Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

@article{Cloughesy2006PhaseIT,
  title={Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.},
  author={Timothy F. Cloughesy and Patrick Yung Wen and H. Ian Robins and Susan M. Chang and Morris D. Groves and Karen L. Fink and Larry R Junck and David Schiff and Lauren E. Abrey and Mark Gilbert and Frank Lieberman and John G. Kuhn and Lisa M DeAngelis and Minesh P. Mehta and Jeff J Raizer and W. K. Alfred Yung and Ken Aldape and John Wright and Kathleen R. Lamborn and Michael D. Prados},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 22},
  pages={
          3651-6
        }
}
PURPOSE A phase II study was undertaken in patients with recurrent malignant glioma to determine the efficacy and safety of tipifarnib, a farnesyltransferase inhibitor, dosed at the respective maximum-tolerated dose (MTD) for patients receiving and not receiving enzyme-inducing antiepileptic drugs (EIAEDs). Because tipifarnib undergoes extensive hepatic metabolism, MTD is doubled in patients on EIAEDs. The population included 67 patients with glioblastoma multiforme (GBM) and an exploratory… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 60 CITATIONS, ESTIMATED 48% COVERAGE

Autophagic and Apoptotic Pathways as Targets for Chemotherapy in Glioblastoma

  • International journal of molecular sciences
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

Cell Signaling Pathways in Brain Tumors

  • Topics in magnetic resonance imaging : TMRI
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2007
2019

CITATION STATISTICS

  • 1 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 26 REFERENCES

A phase-1 study of CPT-11 given every 3 weeks to patients with recurrent malignant glioma: A North American Brain Tumor Consortium (NABTC) study

M Prados, J Kuhn, WKA Yung
  • Proc Am Soc Clin Oncol 19:162a,
  • 2000
VIEW 14 EXCERPTS
HIGHLY INFLUENTIAL

Phase I trial of R115777 (Zarnestra) in patients with recurrent Table 3. Safety Adverse Event Not Receiving EIAEDs (group A; n 46) Receiving EIAEDs (group B

JG Kuhn, M Prados, HI Robins
  • Any Grade No. of Patients
  • 2006
VIEW 1 EXCERPT

A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
VIEW 1 EXCERPT

NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
VIEW 1 EXCERPT